We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

60 hedge funds and large institutions have $14.8M invested in Galectin Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

523% more call options, than puts

Call options by funds: $187K | Put options by funds: $30K

84% more capital invested

Capital invested by funds: $8.05M → $14.8M (+$6.78M)

0.1% more ownership

Funds ownership: 11.97% → 12.07% (+0.1%)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

2% less funds holding

Funds holding: 61 → 60 (-1)

40% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 15

Holders
60
Holders Change
-1
Holders Change %
-1.64%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
15
Closed
6
Calls
$187K
Puts
$30K
Net Calls
+$157K
Net Calls Change
+$164K

Top Buyers

Rank Fund Capital Flow
1
WANY
Wealthspire Advisors (New York)
New York
+$297K
2
Morgan Stanley
Morgan Stanley
New York
+$242K
3
IAA
Independent Advisor Alliance
North Carolina
+$58.3K
4
HKAM
Horizon Kinetics Asset Management
New York
+$48.4K
5
Wells Fargo
Wells Fargo
California
+$31.9K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$209K
2
Citadel Advisors
Citadel Advisors
Florida
-$133K
3
VF
Virtu Financial
New York
-$44K
4
BFEC
Benjamin F. Edwards & Company
Missouri
-$40.8K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
51
Fidelity Investments
Massachusetts
$6.72K +$5.17K +3,200 New
SIS
52
Sound Income Strategies
Florida
$6.26K +$4.81K +2,980 New
Citadel Advisors
53
Citadel Advisors
Florida
$2.68K -$133K -82,356 -98%
BAM
54
Belpointe Asset Management
Nevada
$2.24K – – –
BCPWM
55
Bradley & Co Private Wealth Management
Florida
$2.1K – – –
GRP
56
Global Retirement Partners
California
$588 – – –
SIC
57
Salem Investment Counselors
North Carolina
$351 – – –
Commonwealth Equity Services
58
Commonwealth Equity Services
Massachusetts
$213 – – –
VF
59
Virtu Financial
New York
– -$44K -39,169 Closed
CF
60
Centaurus Financial
California
– -$23K -20,732 Closed
Rockefeller Capital Management
61
Rockefeller Capital Management
New York
– -$10K -8,886 Closed
UBS Group
62
UBS Group
Switzerland
– -$6.28K -5,561 Closed
GWSA
63
Global Wealth Strategies & Associates
Colorado
– -$1.13K -1,000 Closed
MCC
64
Money Concepts Capital
Florida
– -$1.13K -1,000 Closed
Royal Bank of Canada
65
Royal Bank of Canada
Ontario, Canada
– +$47 +29 New
1 2
3

GALT Hedge Fund Activity: Q1 2023 in Review

60 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2023, worth a combined $14.8M — up 84% from $8.05M a quarter earlier.

Fund positioning in GALT was balanced in Q1 2023: 6 funds opened new positions, 6 closed out, 9 added to existing stakes and 15 trimmed.

The largest buyer was Wealthspire Advisors (New York), opening a new position worth an estimated $297K. The largest seller was Millennium Management, cutting an estimated $209K.

  • 60 institutional investors held Galectin Therapeutics (GALT) as of Q1 2023, down from 61 in Q4 2022.
  • Funds reported $14.8M of Galectin Therapeutics stock for Q1 2023, up 84% quarter-over-quarter.
  • 6 funds opened new Galectin Therapeutics positions in Q1 2023 and 6 closed out, a net change of 0 holders.
  • The largest Galectin Therapeutics buyer in Q1 2023 was Wealthspire Advisors (New York), an estimated $297K added.
  • The largest Galectin Therapeutics seller in Q1 2023 was Millennium Management, an estimated $209K sold.

Based on aggregated 13F filings for Q1 2023.